User profiles for K. S. Bauer
Kevin BauerMIT Lincoln Laboratory Verified email at ll.mit.edu Cited by 2299 |
[PDF][PDF] Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
…, R Messmann, D Headlee, KS Bauer… - Journal of Clinical …, 2001 - researchgate.net
Purpose: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-…
the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-…
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
KS Bauer, SC Dixon, WD Figg - Biochemical pharmacology, 1998 - Elsevier
Thalidomide has been shown to be an inhibitor of angiogenesis in a rabbit cornea micropocket
model; however, it has failed to demonstrate this activity in other models. These results …
model; however, it has failed to demonstrate this activity in other models. These results …
Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study
BJ Dezube, SE Krown, JY Lee, KS Bauer… - Journal of clinical …, 2006 - ascopubs.org
… overexpressed in Kaposi's sarcoma (KS) cells. In a phase I trial of the MMP inhibitor COL-3
in patients with AIDS-related KS, the drug was well tolerated, KS regression was observed, …
in patients with AIDS-related KS, the drug was well tolerated, KS regression was observed, …
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory …
KS Bauer, JE Karp, TS Garimella, S Wu, M Tan… - Leukemia research, 2005 - Elsevier
… KS Bauer interpreted and analyzed the data, provided drafting of the article, provided critical
revisions and important intellectual content, and gave final approval. JE Karp contributed to …
revisions and important intellectual content, and gave final approval. JE Karp contributed to …
[PDF][PDF] An Empirical Evaluation of Relay Selection in Tor.
… distributions), we find a Kolmogorov-Smirnov (KS) statistic of 0.050 between the 1524-relay
model and the live network, and a KS statistic of 0.065 between the 50-relay model and the …
model and the live network, and a KS statistic of 0.065 between the 50-relay model and the …
Methodically Modeling the Tor Network.
Live Tor network experiments are difficult due to Tor’s distributed nature and the privacy
requirements of its client base. Alternative experimentation approaches, such as simulation and …
requirements of its client base. Alternative experimentation approaches, such as simulation and …
Family structure: Its effects on adolescent attachment and identity formation
AJ Faber, AE Edwards, KS Bauer… - The American Journal of …, 2003 - Taylor & Francis
This quantitative study examines the association between family structure, attachment, and
identity formation. Results partially support the hypotheses and indicate that unresolved …
identity formation. Results partially support the hypotheses and indicate that unresolved …
Pharmacokinetics of thalidomide in an elderly prostate cancer population
WD Figg, S Raje, KS Bauer, A Tompkins… - Journal of …, 1999 - Wiley Online Library
… Bauer et al. went on to show that a metabolite of thalidomide was responsible for the antian…
Bauer, KS; Dixon, SC; Figg, WD Inhibition of angiogenesis by thalidomide requires metabolic …
Bauer, KS; Dixon, SC; Figg, WD Inhibition of angiogenesis by thalidomide requires metabolic …
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis
T Nakanishi, LA Doyle, B Hassel, Y Wei, KS Bauer… - Molecular …, 2003 - ASPET
To evaluate the function and substrate specificity of human breast cancer resistance protein
(BCRP, ABCG2) in the absence of cofactors or heterologous partner proteins, Xenopus …
(BCRP, ABCG2) in the absence of cofactors or heterologous partner proteins, Xenopus …
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
…, S Luger, MR Baer, KJ Norsworthy, KS Bauer… - Investigational new …, 2013 - Springer
Background The PI3K-Akt pathway is frequently activated in acute leukemias and represents
an important therapeutic target. UCN-01 and perifosine are known to inhibit Akt activation. …
an important therapeutic target. UCN-01 and perifosine are known to inhibit Akt activation. …